ZyVersa Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

ZyVersa Therapeutics has a total shareholder equity of $8.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $19.5M and $10.8M respectively.

Belangrijke informatie

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsratio	n/a
Contant	US$119.49k
Aandelen	US$8.62m
Totaal verplichtingen	US$10.85m
Totaal activa	US$19.47m

Recente financiële gezondheidsupdates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: ZVSA's short term assets ($641.4K) do not cover its short term liabilities ($10.0M).

Langlopende schulden: ZVSA's short term assets ($641.4K) do not cover its long term liabilities ($854.6K).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: ZVSA is debt free.

Schuld verminderen: ZVSA had no debt 5 years ago.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: ZVSA has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.

Voorspelling contante baan: ZVSA is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.

ZyVersa Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

ZyVersa Therapeutics Receives Letter of Reprimand from Nasdaq in Accordance with Nasdaq’s Listing Rule 5810(c)(4)

ZyVersa Therapeutics Receives Approval from Nasdaq to Transfer the Listing of Common Stock from the Nasdaq Global Market to the Nasdaq Capital Market

Nasdaq Issues A Letter to ZyVersa Therapeutics, Inc. Regarding Listing Rule 5810(c)(3)(A)(iii)

Nasdaq Issues A Letter to ZyVersa Therapeutics, Inc. Regarding Listing Rule 5810(c)(3)(A)(iii)

ZyVersa Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq

ZyVersa Therapeutics, Inc. announced delayed 10-Q filing

Recent updates

ZyVersa Therapeutics, Inc. Forms New Scientific Advisory Board

ZyVersa Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.397396 million.

ZyVersa Therapeutics, Inc., Annual General Meeting, Oct 29, 2024

ZyVersa Therapeutics, Inc. Announces Publish Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

ZyVersa Therapeutics, Inc. Announces IRB Approval of Phase 2A Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease

ZyVersa Therapeutics Receives Letter of Reprimand from Nasdaq in Accordance with Nasdaq’s Listing Rule 5810(c)(4)

ZyVersa Therapeutics Receives Approval from Nasdaq to Transfer the Listing of Common Stock from the Nasdaq Global Market to the Nasdaq Capital Market

ZyVersa Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.99964 million.

Nasdaq Issues A Letter to ZyVersa Therapeutics, Inc. Regarding Listing Rule 5810(c)(3)(A)(iii)

Nasdaq Issues A Letter to ZyVersa Therapeutics, Inc. Regarding Listing Rule 5810(c)(3)(A)(iii)

High number of new and inexperienced directors

ZyVersa Therapeutics, Inc. has filed a Follow-on Equity Offering.

ZyVersa Therapeutics, Inc. has filed a Follow-on Equity Offering.

ZyVersa Therapeutics, Inc. Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating that Inflammasome ASC Inhibitor IC 100 Attenuates Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection

ZyVersa Therapeutics, Inc. Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100's Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease

ZyVersa Therapeutics, Inc. Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues

Zyversa Therapeutics Announces Research Published in the Journal of Clinical Investigation Reinforcing Ic 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues

Zyversa Therapeutics, Inc. Announces Research Published in Frontiers in Immunology Reinforcing Ic 100'S Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases

ZyVersa Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq

ZyVersa Therapeutics, Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2023

ZyVersa Therapeutics, Inc., Annual General Meeting, Oct 31, 2023

ZyVersa Therapeutics, Inc. announced delayed 10-Q filing

ZyVersa Therapeutics, Inc. Announces European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator™? VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease

ZyVersa Therapeutics, Inc. Announces Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arterial Disease

ZyVersa Therapeutics Receives Non-Compliance Letter Form Nasdaq

European Patent Office to Grant Zyversa Therapeutics' Patent Application for Cholesterol Transport Mediator™? Var 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease

ZyVersa Therapeutics, Inc. Announces Changes to Board of Directors

ZyVersa Therapeutics, Inc. Appoints Dr. Pablo Guzman as Chief Medical Officer and Senior Vice President of Medical Affairs

Less than half of directors are independent

ZyVersa Therapeutics, Inc. Announces Executive Changes

ZyVersa Therapeutics, Inc. Adds Two Esteemed Leaders to Its Renal Scientific Advisory Board

High number of new directors

No independent directors

ZyVersa Therapeutics, Inc. completed the acquisition of Larkspur Health Acquisition Corp. (NasdaqGM:LSPR) from Larkspur Health LLC, A.G.P. / Alliance Global Partners Corp. and others in a reverse merger transaction.

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven